Similar Articles
What is the Effect of Accompanying Ankylosing Spondylitis in Treatment of Multiple Sclerosis? Is there a Resistance
Ezgi Akyıldız Tezcan, Hakan Ekmekçi, Gökhan Özdemir, Haluk Gümüş, Şerefnur Öztürk
DOI: 10.4274/tnd.2019.93206
Coexistence of Ankylosing Spondylitis and Multiple Sclerosis: Trigger with TNF-alpha Antagonist Therapy or Coincidental?
Bahar Say, Ufuk Ergün
DOI: 10.4274/tnd.2019.87513
Prognostic Value of Serum Neurofilaments in Patients with Clinically Isolated Syndromes
İpek Güngör Doğan
DOI: 10.4274/tnd.2019.97720
The Adverse Effects of High-dose Corticosteroids with Early and Late Severe Morbidity in the Treatment of Patients with Multiple Sclerosis: Long-term Observation Results
Sami Ömerhoca, Sinem Yazıcı Akkaş, Zerrin Yıldırım Haşimoğlu, Sebatiye Erdoğan, Nilüfer Kale
DOI: 10.4274/tnd.2019.75725
Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
Halil Önder
DOI: 10.4274/tnd.2019.05925
Analysis of Peripapillary Retinal Nerve Fiber Layer and Macular Volume in Patients with Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, and Healthy Controls Using Spectral Domain Optical Coherence Tomography in a Turkish Cohort
Ayşe İlksen Çolpak, Duygu Gülmez Sevim, Aslı Tuncer, Sevda Diker, Rana Karabudak, Sibel Kadayıfçılar, Tülay Kansu
DOI: 10.4274/tnd.2018.33230
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
Miraç Ayşen Ünsal
DOI: 10.4274/tnd.2019.00187
Prognostic-disability Biomarkers in Multiple Sclerosis: Review of the Literature from the Last Five Years
Nefati Kıylıoğlu
DOI: 10.4274/tnd.79836
Posterior Auricular Muscle Response: Observations in Brainstem Lesions
Yeşim Gülen Abanoz, Yasin Abanoz, Yasemin Akıncı, Ayşegül Gündüz, Eser Buluş, Melih Tütüncü, Sabahattin Saip, Meral Erdemir Kızıltan
DOI: 10.4274/tnd.57255
Peripheral Blood B Cell Distribution of Patients with Multiple Sclerosis
Joob Beuy, Viroj Wiwanitkit
DOI: 10.4274/tnd.86977
Mortality in Patients with Multiple Sclerosis
Sümeyra Şamlı, Murat Kürtüncü
DOI: 10.4274/tnd.15921
Fampridine Therapy in Multiple Sclerosis: We Should Think Twice!
Mohamed S A Mohamed
DOI: 10.4274/tnd.65882
Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
Burcu Altunrende, Erkingül Birday, Mithat Kasap, Gülşen Akman Demir
DOI: 10.4274/tnd.62144
Quality of Life, Coping, and Social Support in Patients with Multiple Sclerosis: A Pilot Study
Oğuzhan Zengin, Ercüment Erbay, Buğra Yıldırım, Özgür Altındağ
DOI: 10.4274/tnd.37074
Flow Cytometry Analysis of Peripheral Blood B Cell Distribution of Patients with Multiple Sclerosis
Vuslat Yılmaz, Deniz Ak Tura, Canan Ulusoy, Duygu Özkan Yaşargün, Suzan Adın Çınar, Recai Türkoğlu
DOI: 10.4274/tnd.87523
Acute Spinal Pseudoathetosis
Mehmet Fevzi Öztekin, Dilara Mermi Dibek
DOI: 10.4274/tnd.27167
Weight Loss and Fingolimod
Nefati Kıylıoğlu
DOI: 10.4274/tnd.87528
The Effect of Ocrelizumab in the Treatment of Multipl Sclerosis
Şenay Yıldız Çelik
DOI: 10.4274/tnd.71354
Amiselimod: A New Oral Agent in the Treatment of Multiple Sclerosis
Ahmed Serkan Emekli
DOI: 10.4274/tnd.90018
The Predictive Role of NEDA in the Long-Term Course of Multiple Sclerosis
Özgü Kizek
DOI: 10.4274/tnd.65391